Company news
Spruce Biosciences, Inc. news in 2024
Spruce Biosciences, Inc.'s news releases, calls and decks from 2024, newest first.
Spruce Biosciences Announces Topline Results from CAHmelia-204 in Adult CAH and CAHptain-205 in Adult and Pediatric CAH
December 9, 2024
Spruce Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
November 10, 2024
Spruce Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
August 11, 2024
Spruce Biosciences and HMNC Brain Health Announce Strategic Collaboration to Develop Treatment for Major Depressive Disorder (MDD)
June 3, 2024
Spruce Biosciences Announces Poster Presentations at the 2024 Annual Meeting of the Endocrine Society
May 21, 2024
Spruce Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates
May 12, 2024
Spruce Biosciences Announces Additional Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting
April 29, 2024
Spruce Biosciences Announces Upcoming Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting
April 21, 2024
Spruce Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates
March 12, 2024
Spruce Biosciences Announces Topline Results from CAHmelia-203 in Adult Classic CAH and CAHptain-205 in Pediatric Classic CAH
March 12, 2024
Spruce Biosciences Completes Enrollment in CAHmelia-204 Study for Adult Classic Congenital Adrenal Hyperplasia
January 21, 2024
Spruce Biosciences Reports Baseline Characteristics from CAHmelia-203 and CAHmelia-204 Studies in Adult Classic CAH
January 4, 2024
Spruce Biosciences Provides Clinical Program Updates and Outlook for 2024
January 3, 2024